about
Emerging therapeutic biomarkers in endometrial cancerEffect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitroAntitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutationsThe mutational landscape of endometrial cancerUterine serous carcinoma: increased familial risk for lynch-associated malignanciesERM/ETV5 and RUNX1/AML1 expression in endometrioid adenocarcinomas of endometrium and association with neoplastic progression.Novel genetic targets in endometrial cancer.The emerging genomic landscape of endometrial cancer.Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5).Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutatedIntegrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivoEpigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma.Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes.HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival.Enolase-1 is a therapeutic target in endometrial carcinoma.The Therapeutic Challenge of Targeting HER2 in Endometrial CancerNEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt signalingThe genomics and genetics of endometrial cancer.Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.New candidate therapeutic agents for endometrial cancer: potential for clinical practice (review).Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers.Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancerThe correlation between microRNA490-3p and TGFα in endometrial carcinoma tumorigenesis and progression.NMU signaling promotes endometrial cancer cell progression by modulating adhesion signaling.Protein Kinase C α Modulates Estrogen-Receptor-Dependent Transcription and Proliferation in Endometrial Cancer Cells.Individualised proteome profiling of human endometrial tumours improves detection of new prognostic markers.Downregulation of claudin-7 potentiates cellular proliferation and invasion in endometrial cancer.
P2860
Q26865904-03A41989-DA12-4D83-B3BD-B051B564907DQ27853018-06AE3A95-87C2-49BC-87A5-7EB129F80863Q27853244-56962992-A1EF-490A-8A95-F76F597F844AQ28084466-D5D11906-1A5B-4AE6-8B4F-DCBA2CE6DF5EQ30422098-D0ED0D7C-C453-48F8-ADE6-3028531E2C92Q33911196-C0D6BED4-1050-45A5-8F75-3C2E40AD9E6EQ34026696-11F12C49-F17F-4FF6-BA9A-84329BFC3008Q34026976-E03D0AF7-26AD-492C-8779-7151DEFB53D5Q34397557-824493E0-F0AC-41E5-80F8-E7135F67E200Q34458796-9C49BEE0-7D29-4FE9-A326-B0B90357BDA4Q34541232-A893057A-0244-406E-B35F-83A470980A72Q34580883-697E19E0-1009-4B7C-A042-5C3B1395E3BAQ34650735-5D195DC2-AED0-43BF-B3BC-E0DCE6E7502DQ34729807-594A4804-D154-46A3-82B2-CF8A1070E4A1Q34807396-A9208AD4-EF66-4D83-BB8F-5AE7BD496B4DQ35051154-F91302F8-EFC7-4A6E-A7AF-3CF70B3EC9C8Q35084900-43EF65AB-B5E0-49DF-A49B-C2F4CB95B60CQ35117286-C7295EEF-94A9-43B6-8093-C865B3C50C19Q35235832-4868460A-2A82-41F6-A49A-F3C674392F5CQ35833089-5BA62B82-05C3-47B5-9929-AD47B5F94562Q35837949-B622D710-11D6-4AB7-85DE-8C422E82E4D9Q35863154-DC7A0C25-BB6D-4CB4-B317-ACA6BB359F19Q36021076-5F62AC5B-E32E-44E3-99EB-4547ED7054D8Q36064912-DBE8C404-579A-4342-9D4A-4D5E225AAFA3Q36101707-1B8EC0CF-A3F3-4CAF-9D55-38FCD49CAC14Q36151896-9AF39194-7356-4286-9B09-5C458095F0D0Q36254394-882F3752-0C52-4B46-A8AD-D8E18DE62F81Q36354855-1D9C5361-894F-4469-985E-1FBBF5140BF1Q36372293-57D499DE-EFCA-4E09-BA7B-203CEC27FBB2Q36418630-0E20C7C8-21C3-409B-8045-41EBB316A8A5Q36451726-B74E48AB-3E25-45FE-A16C-791ACA90C3D4Q36684551-9110CB37-10F5-4CDD-BB52-AFB164A6E20EQ36746785-D3FF5AF6-2CFF-40D5-83FC-3A153294DDB3Q36788196-DB9AD007-BAC7-4B7E-89AB-A642955523D1Q36801208-F4A1E08B-2C66-4BAC-92EF-6794D1097949Q36962563-E016F259-8589-4963-B681-C2B160FD81C7Q36962930-F9C46CAC-D752-4534-BF60-F63FCFABA622Q36988609-5898695E-5032-4A26-8487-6DA0F032CAD5Q37081947-EA8061EB-A630-4984-B768-B313E1D7B7CEQ37092609-60A8AA25-1D7F-4AEE-831E-D23DC7421121
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging therapeutic targets in endometrial cancer.
@en
Emerging therapeutic targets in endometrial cancer.
@nl
type
label
Emerging therapeutic targets in endometrial cancer.
@en
Emerging therapeutic targets in endometrial cancer.
@nl
prefLabel
Emerging therapeutic targets in endometrial cancer.
@en
Emerging therapeutic targets in endometrial cancer.
@nl
P2093
P2860
P3181
P1476
Emerging therapeutic targets in endometrial cancer.
@en
P2093
Daniel Wetterskog
Konstantin J Dedes
Stan B Kaye
P2860
P304
P356
10.1038/NRCLINONC.2010.216
P407
P577
2011-01-11T00:00:00Z